platinum has been researched along with sirolimus in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barry, JJ; Casey, MA; Feygin, JM; Huibregtse, BA; Pennington, DE; Soucy, NV; Tunstall, R | 1 |
| Allocco, DJ; Dawkins, KD; El-Jack, S; Meredith, IT; Scott, D; Starzyk, RM; Stone, GW; Teirstein, PS; Whitbourn, R; Zambahari, R | 1 |
| Calais, F; Carlsson, J; Götberg, M; James, S; Lagerqvist, B; Nilsson, J; Nilsson, T; Olivecrona, G; Sarno, G; Sjögren, I | 1 |
| Cha, KS; Chae, IH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, SH; Kim, HS; Kim, S; Kwon, HM; Lee, SP; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, JJ; Park, KW; Park, TH; Rhew, JY; Shin, ES; Yoon, JH | 1 |
| Büttner, HJ; Gick, M; Leibundgut, G; Löffelhardt, N; Neumann, FJ; Toma, A; Valina, C | 1 |
| Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
| De la Torre Hernandez, JM; Garcia Camarero, T; Gorria, GM; Lee, DH; Lerena, P; Sainz Laso, F; Zueco, J | 1 |
| Allocco, DJ; Cannon, LA; Dawkins, KD; Dens, J; Dubois, CL; Feldman, RL; Lee, TC; Meredith, IT; Mooney, MR; Pompili, VJ; Rabinowitz, AC; Saito, S; Stone, GW; Teirstein, PS | 1 |
| Abbott, JD; Srour, JF | 1 |
| Allocco, DJ; Amjadi, N; Caputo, C; Christen, T; Dawkins, KD; Kandzari, DE; Rowe, SK; Tamboli, HP; Williams, J | 1 |
| Allocco, DJ; Chen, J; Dawkins, KD; Fu, G; Han, Y; Hong, T; Jiang, T; Li, H; Liu, H; Pang, W; Su, X; Sun, F; Wang, H; Xu, K; Yang, Y; Yuan, Z; Zhang, J; Zhang, M | 1 |
| Dauler, M; Haldis, TA; Maehara, A; Mehran, R; Myers, P; Peng, Y; Popma Almonacid, A; Price, MJ; Shlofmitz, RA; Spriggs, DJ | 1 |
| Ahn, T; Bae, JH; Cha, KS; Han, KR; Jeon, KH; Kang, HJ; Kim, HS; Kim, SH; Koo, BK; Kwon, HM; Lee, JM; Lee, MS; Oh, SK; Park, KW; Park, SH; Park, WJ; Rha, SW; Rhee, TM; Rhew, JY; Seung, KB | 1 |
| Cha, KS; Chae, IH; Hur, SH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, J; Kim, CH; Kim, HS; Kim, S; Kwon, HM; Lee, BR; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, KW; Park, TH; Park, YW; Rhew, JY; Ryu, JK; Shin, ES; Yoon, JH | 1 |
7 trial(s) available for platinum and sirolimus
| Article | Year |
|---|---|
The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.
Topics: Angioplasty, Balloon, Coronary; Chromium; Chromium Alloys; Coronary Stenosis; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Humans; Platelet Aggregation Inhibitors; Platinum; Prospective Studies; Prosthesis Design; Republic of Korea; Research Design; Single-Blind Method; Sirolimus; Time Factors; Treatment Outcome | 2012 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
A real all-comers randomized trial comparing Xience Prime and Promus Element stents.
Topics: Aged; Angina, Stable; Angina, Unstable; Chromium Alloys; Coronary Restenosis; Drug-Eluting Stents; Equipment Failure; Everolimus; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Sirolimus; Thrombosis; Treatment Outcome | 2013 |
Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
Topics: Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Japan; Male; Middle Aged; New Zealand; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Sirolimus; Time Factors; Treatment Outcome; United States | 2015 |
A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study.
Topics: Adolescent; Adult; Aged; China; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Polymers; Sirolimus; Treatment Outcome; Young Adult | 2017 |
Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial.
Topics: Aged; Angina, Stable; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Iridium; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Risk Factors; Sirolimus; Time Factors; Treatment Outcome; Ultrasonography, Interventional; United States | 2018 |
Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.
Topics: Aged; Chromium; Chromium Alloys; Coronary Angiography; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Failure; Sirolimus | 2019 |
7 other study(ies) available for platinum and sirolimus
| Article | Year |
|---|---|
Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating.
Topics: Angioplasty, Balloon, Coronary; Animals; Chromium; Coronary Vessels; Drug-Eluting Stents; Endothelial Cells; Everolimus; Female; Immunosuppressive Agents; Metals; Microscopy, Electron, Scanning; Platelet Endothelial Cell Adhesion Molecule-1; Platinum; Prosthesis Design; Rabbits; Sirolimus; Stents | 2010 |
PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platinum; Prospective Studies; Sirolimus; Ultrasonography, Interventional | 2011 |
Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Aged; Angioplasty, Balloon, Coronary; Chromium; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Platinum; Registries; Sirolimus; Sweden; Treatment Outcome | 2013 |
Longitudinal compression of the platinum-chromium everolimus-eluting stent during coronary implantation: predisposing mechanical properties, incidence, and predictors in a large patient cohort.
Topics: Aged; Cardiovascular Agents; Chi-Square Distribution; Chromium; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Equipment Failure Analysis; Everolimus; Female; Humans; Logistic Models; Male; Materials Testing; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stress, Mechanical; Tomography, Optical Coherence; Treatment Outcome | 2013 |
Small vessels and long lesions: changing label indications for drug eluting stents.
Topics: Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platinum; Sirolimus | 2015 |
One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]).
Topics: Adult; Aged; Aged, 80 and over; Chromium; Coronary Angiography; Coronary Artery Disease; Device Approval; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Registries; Sirolimus; Time Factors; Treatment Outcome; United States | 2016 |
Predictors and Long-Term Clinical Outcome of Longitudinal Stent Deformation: Insights From Pooled Analysis of Korean Multicenter Drug-Eluting Stent Cohort.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery Disease; Databases, Factual; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Republic of Korea; Risk Factors; Sirolimus; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2017 |